Opioid-induced constipation

References

• WHO’s cancer pain ladder for adults. WHO. Available at http://www.who.int/cancer/palliative/painladder/en/.
   Google Scholar
• Kenan K, Mack K, Paulozzi L. Trends in prescriptions for oxycodone and other commonly used opioids in the United States, 2000-2010. Open Med 2012;6:e41–7.
   PubMedGoogle Scholar
• Kurz A, Sessler DI. Opioid-induced bowel dysfunction: pathophysiology and potential new therapies. Drugs 2003;63:649–71.
   PubMed Web of Science ®Google Scholar
• Holmes S. Use of a modified symptom distress scale in assessment of the cancer patient. Int J Nurs Stud 1989;26:69–79.
   PubMed Web of Science ®Google Scholar
• Wood JD, Galligan JJ. Function of opioids in the enteric nervous system. Neurogastroenterol Motil2004;16:17–28.
   PubMed Web of Science ®Google Scholar
• Stefano GB, Goumon Y, Casares F, Cadet P, Fricchione GL, Rialas C, et al. Endogenous morphine. Trends Neurosci 2000;23:436–42.
   PubMed Web of Science ®Google Scholar
• Kalso E, Edwards JE, Moore RA, McQuay HJ. Opioids in chronic non-cancer pain: systematic review of efficacy and safety. Pain 2004;112:372–80.
   PubMed Web of Science ®Google Scholar
• Pappagallo M. Incidence, prevalence, and management of opioid bowel dysfunction. Am J Surg 2001;182:11S–8S.
   PubMed Web of Science ®Google Scholar
• Bell TJ, Panchal SJ, Miaskowski C, Bolge SC, Milanova T, Williamson R. The prevalence, severity, and impact of opioid-induced bowel dysfunction: results of a US and European Patient Survey (PROBE 1). Pain Med 2009;10:35–42.
   PubMed Web of Science ®Google Scholar
• Rogers M, Cerda JJ. The narcotic bowel syndrome. J Clin Gastroenterol 1989;11:132–5.
   PubMed Web of Science ®Google Scholar
• Grunkemeier DM, Cassara JE, Dalton CB, Drossman DA. The narcotic bowel syndrome: clinical features, pathophysiology, and management. Clin Gastroenterol Hepatol 2007;5:1126–39; quiz 1121-1122.
   PubMed Web of Science ®Google Scholar
• Droney J, Ross J, Gretton S, Welsh K, Sato H, Riley J. Constipation in cancer patients on morphine. Support Care Cancer 2008;16:453–9.
   PubMed Web of Science ®Google Scholar
• Thomas J, Karver S, Cooney GA, Chamberlain BH, Watt CK, Slatkin NE, et al. Methylnaltrexone for opioid-induced constipation in advanced illness. N Engl J Med 2008;358:2332–43.
   PubMed Web of Science ®Google Scholar
• Camilleri M. Opioid-induced constipation: challenges and therapeutic opportunities. Am J Gastroenterol 2011;106:835–42; quiz 843.
   PubMed Web of Science ®Google Scholar
• Tamayo AC, Diaz-Zuluaga PA. Management of opioid-induced bowel dysfunction in cancer patients. Support Care Cancer 2004;12:613–18.
   PubMed Web of Science ®Google Scholar
• Ahmedzai SH, Boland J. Constipation in people prescribed opioids. BMJ Clin Evid 2010;4:2407.
   Google Scholar
• Ishihara M, Ikesue H, Matsunaga H, Suemaru K, Kitaichi K, Suetsugu K, et al. A multi-institutional study analyzing effect of prophylactic medication for prevention of opioid-induced gastrointestinal dysfunction. Clin J Pain 2012;28:373–81.
   PubMed Web of Science ®Google Scholar
• Villars P, Dodd M, West C, Koetters T, Paul SM, Schumacher K, et al. Differences in the prevalence and severity of side effects based on type of analgesic prescription in patients with chronic cancer pain. J Pain Symptom Manage 2007;33:67–77.
   PubMed Web of Science ®Google Scholar
• Rosti G, Gatti A, Costantini A, Sabato AF, Zucco F. Opioid-related bowel dysfunction: prevalence and identification of predictive factors in a large sample of Italian patients on chronic treatment. Eur Rev Med Pharmacol Sci 2010;14:1045–50.
   Web of Science ®Google Scholar
• De Schepper HU, Cremonini F, Park MI, Camilleri M. Opioids and the gut: pharmacology and current clinical experience. Neurogastroenterol Motil 2004;16:383–94.
   PubMed Web of Science ®Google Scholar
• Manara L, Bianchetti A. The central and peripheral influences of opioids on gastrointestinal propulsion. Annu Rev Pharmacol Toxicol 1985;25:249–73.
   PubMed Web of Science ®Google Scholar
• Reimer K, Hopp M, Zenz M, Maier C, Holzer P, Mikus G, et al. Meeting the challenges of opioid-induced constipation in chronic pain management - a novel approach. Pharmacology 2009;83:10–17.
   PubMed Web of Science ®Google Scholar
• Candy B, Jones L, Goodman ML, Drake R, Tookman A. Laxatives or methylnaltrexone for the management of constipation in palliative care patients. Cochrane Database Syst Rev 2011:CD003448.
   Google Scholar
• Tack J. Current and future therapies for chronic constipation. Best Pract Res Clinl Gastroenterol 2011;25:151–8.
   PubMed Web of Science ®Google Scholar
• Latasch L, Zimmermann M, Eberhardt B, Jurna I. Treament of morphine-induced constipation with oral naloxone. Anaesthesist 1997;46:191–4.
   PubMed Web of Science ®Google Scholar
• Culpepper-Morgan JA, Inturrisi CE, Portenoy RK, Foley K, Houde RW, Marsh F, et al. Treatment of opioid-induced constipation with oral naloxone: a pilot study. Clin Pharmacol Ther 1992;52:90–5.
   PubMed Web of Science ®Google Scholar
• Holzer P. New approaches to the treatment of opioid-induced constipation. Eur Rev Med Pharmacol Sci 2008;12:119–27.
   PubMed Web of Science ®Google Scholar
• Bream-Rouwenhorst HR, Cantrell MA. Alvimopan for postoperative ileus. Am J Health Syst Pharm 2009;66:1267–77.
   PubMed Web of Science ®Google Scholar
• Jansen JP, Lorch D, Langan J, Lasko B, Hermanns K, Kleoudis CS, et al. A randomized, placebo-controlled phase 3 trial (Study SB-767905/012) of alvimopan for opioid-induced bowel dysfunction in patients with non-cancer pain. J Pain 2011;12:185–93.
   PubMed Web of Science ®Google Scholar
• Bader S, Jaroslawski K, Blum HE, Becker G. Opioid-induced constipation in advanced illness: safety and efficacy of methylnaltrexone bromide. Clin Med Insight Oncol 2011;5:201–11.
   PubMedGoogle Scholar
• Yuan CS, Foss JF, O’Connor M, Karrison T, Osinski J, Roizen MF, et al. Effects of enteric-coated methylnaltrexone in preventing opioid-induced delay in oral-cecal transit time. Clin Pharmacol Ther 2000;67:398–404.
   PubMed Web of Science ®Google Scholar
• Yuan CS, Foss JF, O’Connor M, Toledano A, Roizen MF, Moss J. Methylnaltrexone prevents morphine-induced delay in oral-cecal transit time without affecting analgesia: a double-blind randomized placebo-controlled trial. Clin Pharmacol Ther 1996;59:469–75.
   PubMed Web of Science ®Google Scholar
• Diego L, Atayee R, Helmons P, von Gunten CF. Methylnaltrexone: a novel approach for the management of opioid-induced constipation in patients with advanced illness. Expert Rev Gastroenterol Hepatol 2009;3:473–85.
   PubMedGoogle Scholar
• Cryer B, Katz S, Vallejo R, Popescu A, Ueno R. A randomized study of lubiprostone for opioid-induced constipation in patients with chronic noncancer pain. Pain Med 2014;15:1825–34.
   PubMed Web of Science ®Google Scholar
• Mackey AC, Green L, Greene P, Avigan M. Methylnaltrexone and gastrointestinal perforation. J Pain Symptom Manage 2010;40:e1–3.
   PubMedGoogle Scholar
• Chey WD, Webster L, Sostek M, Lappalainen J, Barker PN, Tack J. Naloxegol for opioid-induced constipation in patients with noncancer pain. N Engl J Med 2014;370:2387–96.
   PubMed Web of Science ®Google Scholar
• Kress HG. Tapentadol and its two mechanisms of action: is there a new pharmacological class of centrally-acting analgesics on the horizon? Eur J Pain 2010;14:781–3.
   PubMed Web of Science ®Google Scholar
• Bee LA, Bannister K, Rahman W, Dickenson AH. Mu-opioid and noradrenergic alpha(2)-adrenoceptor contributions to the effects of tapentadol on spinal electrophysiological measures of nociception in nerve-injured rats. Pain 2011;152:131–9.
   PubMed Web of Science ®Google Scholar
• Afilalo M, Etropolski MS, Kuperwasser B, Kelly K, Okamoto A, Van Hove I, et al. Efficacy and safety of Tapentadol extended release compared with oxycodone controlled release for the management of moderate to severe chronic pain related to osteoarthritis of the knee: a randomized, double-blind, placebo- and active-controlled phase III study. Clin Drug Invest 2010;30:489–505.
   PubMed Web of Science ®Google Scholar
• Buynak R, Shapiro DY, Okamoto A, Van Hove I, Rauschkolb C, Steup A, et al. Efficacy and safety of tapentadol extended release for the management of chronic low back pain: results of a prospective, randomized, double-blind, placebo- and active-controlled Phase III study. Expert Opin Pharmacother 2010;11:1787–804.
   PubMed Web of Science ®Google Scholar
• Candiotti KA, Gitlin MC. Review of the effect of opioid-related side effects on the undertreatment of moderate to severe chronic non-cancer pain: tapentadol, a step toward a solution? Curr Med Res Opin 2010;26:1677–84.
   PubMed Web of Science ®Google Scholar
• Imanaka K, Tominaga Y, Etropolski M, van Hove I, Ohsaka M, Wanibe M, et al. Efficacy and safety of oral tapentadol extended release in Japanese and Korean patients with moderate to severe, chronic malignant tumor-related pain. Curr Med Res Opin 2013;29:1399–409.
   PubMed Web of Science ®Google Scholar
• Kress HG, Koch ED, Kosturski H, Steup A, Karcher K, Lange B, et al. Tapentadol prolonged release for managing moderate to severe, chronic malignant tumor-related pain. Pain Physician 2014;17:329–43.
   PubMed Web of Science ®Google Scholar
• Meissner W, Schmidt U, Hartmann M, Kath R, Reinhart K. Oral naloxone reverses opioid-associated constipation. Pain 2000;84:105–9.
   PubMed Web of Science ®Google Scholar
• Sykes NP. An investigation of the ability of oral naloxone to correct opioid-related constipation in patients with advanced cancer. Palliat Med 1996;10:135–44.
   PubMed Web of Science ®Google Scholar
• Vondrackova D, Leyendecker P, Meissner W, Hopp M, Szombati I, Hermanns K, et al. Analgesic efficacy and safety of oxycodone in combination with naloxone as prolonged release tablets in patients with moderate to severe chronic pain. J Pain 2008;9:1144–54.
   PubMed Web of Science ®Google Scholar
• Meissner W, Leyendecker P, Mueller-Lissner S, Nadstawek J, Hopp M, Ruckes C, et al. A randomised controlled trial with prolonged-release oral oxycodone and naloxone to prevent and reverse opioid-induced constipation. Eur J Pain 2009;13:56–64.
   PubMed Web of Science ®Google Scholar
• DePriest AZ, Miller K. Oxycodone/Naloxone: role in chronic pain management, opioid-induced constipation, and abuse deterrence. Pain Ther 2014;3:1–15.
   PubMedGoogle Scholar
• Lembo AJ, Schneier HA, Shiff SJ, Kurtz CB, MacDougall JE, Jia XD, et al. Two randomized trials of linaclotide for chronic constipation. N Engl J Med 2011;365:527–36.
   PubMed Web of Science ®Google Scholar
• Lacy BE, Levy LC. Lubiprostone: a chloride channel activator. J Clin Gastroenterol 2007;41:345–51.
   PubMed Web of Science ®Google Scholar
• NCCN Guidelines Adult Cancer Pain (Version 2.2013). Available at http://www.nccn.org/professionals/physician_gls/PDF/pain.pdf.
   Google Scholar
• Donner B, Zenz M, Tryba M, Strumpf M. Direct conversion from oral morphine to transdermal fentanyl: a multicenter study in patients with cancer pain. Pain 1996;64:527–34.
   PubMed Web of Science ®Google Scholar
• Mystakidou K, Tsilika E, Parpa E, Kouloulias V, Kouvaris I, Georgaki S, et al. Long-term cancer pain management in morphine pre-treated and opioid naive patients with transdermal fentanyl. Int J Cancer J 2003;107:486–92.
   PubMed Web of Science ®Google Scholar
• Gyawali B, Tsukuura H, Honda K, Shimokata T, Ando Y. Some questions on the randomized controlled trial of communication skills training for oncologists. J Clin Oncol 2015;33:222.
   Google Scholar